GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
World game at war: why some European nations have threatened a World Cup boycott 
LAKE FOREST, Ill., May 03, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first-quarter 2018 financial results on Thursday, May 10, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results.
Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
Audio Conference Call:
| U.S. Dial-in Number: | 1-877-326-2337 |
| International Dial-in Number: | 1-631-456-4258 |
| Conference ID: | 1328285277 |
An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
John B. Thomas
SVP, Investor Relations and Corporate Communications
[email protected]
